Meibomian Gland Dysfunction
Conditions
Brief summary
Assessor-masked (Single blind, randomized controlled trial comparing the conventional treatment group to an interventional group using 16% Manuka Honey topical eye drops.
Detailed description
Purpose To evaluate the effects of conventional treatment compared to use of Manuka Honey eye drops in the treatment of meibomian gland dysfunction related dry eye disease. Design Assessor-masked (Single blind, randomized controlled trial comparing the conventional treatment group to an interventional group using 16% Manuka Honey topical eye drops. Methods Patients were randomized into two groups, one group given conventional treatment for meibomian gland dysfunction. The other group was given additional manuka honey 16% eye drops which are registered as a medical device by the australian FDA. SPEED score was taken at baseline and upon follow up. Multiple parameters were graded from slit lamp examination by a masked assessor. Results were compared from baseline to follow up date 3 weeks later.
Interventions
DEVICEmanuka honey 16% eye drops ( Optimel )
16% manuka honey eye drops, australian FDA approved
DEVICEsystane eye drops
systane lubricant eye drops
Sponsors
Chinese University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* meibomian gland dysfunction stage 2-4
Exclusion criteria
* \<18 years old Unable to consent Recent ophthalmic surgery \<6m Abnormalities of lid position Allergy to honey/bee products Contact lens wearers Patients on long term topical medications apart from lubricants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| speed score | 3 weeks | questionnaire |
Countries
China
Outcome results
None listed